Lipocine (LPCN) Enterprise Value (2016 - 2025)
Lipocine (LPCN) has disclosed Enterprise Value for 13 consecutive years, with -$15.1 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Enterprise Value rose 5.91% year-over-year to -$15.1 million, compared with a TTM value of -$15.1 million through Sep 2025, changed N/A, and an annual FY2024 reading of -$21.6 million, up 1.83% over the prior year.
- Enterprise Value was -$15.1 million for Q3 2025 at Lipocine, up from -$17.9 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$15.1 million in Q3 2025 and bottomed at -$87.4 million in Q4 2021.
- Average Enterprise Value over 5 years is -$34.5 million, with a median of -$34.3 million recorded in 2022.
- The sharpest move saw Enterprise Value tumbled 353.1% in 2021, then surged 64.14% in 2023.
- Year by year, Enterprise Value stood at -$87.4 million in 2021, then increased by 29.72% to -$61.5 million in 2022, then surged by 64.14% to -$22.0 million in 2023, then grew by 1.83% to -$21.6 million in 2024, then skyrocketed by 30.06% to -$15.1 million in 2025.
- Business Quant data shows Enterprise Value for LPCN at -$15.1 million in Q3 2025, -$17.9 million in Q2 2025, and -$19.7 million in Q1 2025.